Embark is a canine genomics and biotechnology company that offers dog DNA testing services to consumers, breeders, and veterinarians. Their goal is to help pet owners better understand their dog's health and risk for heritable diseases, and to advance canine DNA research.

Embark

Embark offers the most comprehensive, most accurate dog DNA test on the market. An Embark dog DNA test gives pet owners information about their dog’s breed, ancestry, health, and more — all with just a simple cheek swab. The company uses twice as much genetic information as any other test available and features the world’s only canine DNA relative finder. Pet owners can use Embark to test for over 210 genetic health conditions, so they can make the best choices for their dog. Launched by two brothers, Embark is an official research partner with Cornell University College of Veterinary Medicine and has a mission to end preventable disease in dogs.

Third Kind Venture Capital

Section 32 F-Prime Capital

FJ Labs

Slow Ventures

Freestyle Capital

Anne Wojcicki

SoftBank Vision Fund

Embark Veterinary

Embark Veterinary is heading to Orlando for VMX 2024! Come on over and meet the team at booth #1978 and be sure to check out our CE session: Let's Get Clinical: Real world management of common testable canine genetic conditions on Monday, January 15th at 5:45 PM.

🐶 🧬 We're excited to share that Embark Veterinary dog DNA tests, including the Embark for Veterinarians 10-pack, the Breed ID, and the Breed + Health tests, are now available on Vetcove.com. 
✨ Buying dog DNA tests has never been easier! ✨ 
✅ Check it out: https://lnkd.in/eZx97t4S 

We’re excited to announce that Amish Desai, who joined Embark in 2022 as chief financial officer, is stepping into a new role as Embark’s CEO! 🌟 With a focus on our core DNA offerings as well as strategic expansions into new channels and products, Amish is dedicated to helping dog owners form stronger bonds with their best friends.

Learn more here:
https://lnkd.in/eWwUqVt6

COM:EMBARKVET

Embark